23rd Feb 2017 14:57
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr S Dingemans | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 22,448 (Deferred) |
| ||
| £0.0000 | 7,483 (Matching) |
| ||
|
| , |
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 29,931 £0.0000 | ||||
e) | Date of the transaction | 2017-02-22 | |||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr S Dingemans | |||
b) | Position/status | Chief Financial Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 22 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.3850 | 10,763 (Deferred) |
| ||
| £16.4007 | 3,589 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 14,352 £16.3889 | ||||
e) | Date of the transaction | 2017-02-22 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
Related Shares:
Glaxosmithkline